Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
04/2003
04/03/2003WO2002000860A3 Novel proteases
04/03/2003WO2000038618A3 SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
04/03/2003US20030066097 Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065173 Therapy for drug abuse
04/03/2003US20030065138 Linear gamma-carboxyglutamate rich conotoxins
04/03/2003US20030065038 Administering N-propargyl-1-aminoindan
04/03/2003US20030065030 Containing carnosine; therapy for nervous system disorders
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065013 Central nervous system analgesic; hypotensive agents; antiarrhythmia agents; antidiabetic agents
04/03/2003US20030065012 Estrogen receptor modulators
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065002 Analgesics; side effect reduction
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064998 Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
04/03/2003US20030064993 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064983 Headaches; antiarthritic agents; respiratory system disorders; psychological disorders
04/03/2003US20030064981 Anticancer agents; antidiabetic agents; Alzheimer's disease
04/03/2003US20030064974 Cognition activator; binding of cortisol to receptor
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064943 High affinity TGFbeta nucleic acid ligands and inhibitors
04/03/2003US20030064942 Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
04/03/2003US20030064938 Cardiovascular disorders; menstraution disorders; anticancer agents
04/03/2003US20030064932 Methods of treatment comprising administration of Substance P
04/03/2003US20030064919 Novel polypeptides and polynucleotides encoding same
04/03/2003US20030064914 Copolymer-1 improvements in compositions of copolymers
04/03/2003US20030064493 Methods and means for modulating PGE synthase activity
04/03/2003US20030064426 Expression vector for use in the treatment of cancer and age-related defects
04/03/2003US20030064412 123 human secreted proteins
04/03/2003US20030064401 Diagnosing psychological disorders in humans; obtain tissue sample humans, test sample for presence of polymorphism in promoter of nerve growth factor, presence of polymorphism indicates psychological disorder
04/03/2003US20030064374 Detecting neuronal stress in humans; obtain sample, measure phosphodiesterase concentration, evaluate for neuronal stress
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064122 Pharmaceutical compound, and an amount of a capsaicin compound to deter intranasal, oral, and intravenous abuse while having little or no irritating effect when administered orally or transdermally as directed
04/03/2003US20030064120 Method for relaxing human beings using personal care compositions
04/03/2003US20030064118 Combination of Ginseng and Ginkgo to improve cognitive skills
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064095 Microfabricated nanopore device for sustained release of therapeutic agent
04/03/2003US20030064092 Pharmaceutical composition containing two active ingredients for smoking cessation
04/03/2003US20030064063 For prophylaxis of type I hypersensitivity disease in a subject receiving immunotherapy
04/03/2003US20030064036 Coating and binding agent for pharmaceutical formulations with improved storage stability
04/03/2003CA2688860A1 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
04/03/2003CA2461731A1 Pharmaceutical compositions for the treatment of urinary disorders
04/03/2003CA2461709A1 Small organic molecule regulators of cell proliferation
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461663A1 Conjugated anti-psychotic drugs and uses thereof
04/03/2003CA2461603A1 Substituted amines for the treatment of neurological disorders
04/03/2003CA2461539A1 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
04/03/2003CA2461467A1 Substituted alkylaminopyridazinone derivatives, process for the preparation thereof and pharmaceutical composition containing the same
04/03/2003CA2461312A1 Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
04/03/2003CA2461305A1 Methods of suppressing microglial activation and systemic inflammatory responses
04/03/2003CA2461186A1 Novel screening method using prokineticin receptor
04/03/2003CA2461150A1 Amines with antialcoholic agents
04/03/2003CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003CA2461095A1 Process for making substituted pyrazoles
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2460000A1 Inhibitors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
04/03/2003CA2459976A1 Opioid formulations having reduced potential for abuse
04/03/2003CA2455989A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/03/2003CA2446904A1 Delivery of drug esters through an inhalation route
04/02/2003EP1298436A2 Beta-amyloid peptide (BAP) release inhibitor compounds for treating BAP-related diseases and methods for their identification
04/02/2003EP1298206A1 Use of the Factor VII-activating protease for prevention and therapy of vaso-proliferative disorders
04/02/2003EP1298124A1 Method For the Preparation of Citalopram
04/02/2003EP1297849A1 Remedial agent for optic nerve disease and the like
04/02/2003EP1297833A1 Indole carboxylic acids as thyroid receptor ligands
04/02/2003EP1297180A2 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions
04/02/2003EP1297142A2 Dual specificity antibodies and methods of making and using
04/02/2003EP1297139A2 G-protein coupled receptor org10
04/02/2003EP1297137A2 Gp286 nucleic acids and polypeptides
04/02/2003EP1297136A2 Full length human hcn1 ih channel subunit and variants
04/02/2003EP1297133A2 Gp354 nucleic acids and polypeptides
04/02/2003EP1297130A2 G-protein coupled receptors
04/02/2003EP1297129A2 Card domain containing polypeptides, encoding nucleic acids, and methods of use
04/02/2003EP1297014A2 Transporters and ion channels
04/02/2003EP1297007A2 Mammalian protein phosphatases
04/02/2003EP1296999A2 Neuroactive peptides for treatment of hypoxia and related conditions
04/02/2003EP1296996A1 Purine derivatives
04/02/2003EP1296988A1 Azepino 4,5-b]pyrano 3,2-e]indoles
04/02/2003EP1296976A1 Novel 1,3-dihydro-2h-indol-one derivatives, method for preparing same and pharmaceutical compositions containing them
04/02/2003EP1296975A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
04/02/2003EP1296972A1 Arylmethylamine derivatives for use as tryptase inhibitors
04/02/2003EP1296970A1 Method for the preparation of citalopram
04/02/2003EP1296961A1 1,4-diazepan-2,5-dione derivatives and their use as nk-1 receptor antagonists
04/02/2003EP1296960A2 5h-2,3-benzodiazepine antagonists of excitatory amino acid receptors
04/02/2003EP1296958A1 Iminopyrimidine nmda nr2b receptor antagonists
04/02/2003EP1296956A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
04/02/2003EP1296954A1 Bicyclic lactams and sulfonamides with 5-ht1a-affinity and use thereof for preventing and treating cerebral ischaemia
04/02/2003EP1296951A1 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
04/02/2003EP1296945A1 Sulfonamide derivatives
04/02/2003EP1296944A1 Sulfonamide derivatives
04/02/2003EP1296943A1 Amino acid derivatives and their use as medicines
04/02/2003EP1296940A1 Amidine derivatives as selective antagonists of nmda receptors
04/02/2003EP1296936A1 Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones
04/02/2003EP1296934A1 Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
1 ... 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 ... 1833